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 18 
Abstract 19 
A novel drug delivery systems based on cationic (CL) and pH-sensitive liposomes (PSL) 20 
for tyrosine kinase inhibitor afatinib (AFT) were developed to enhance tumor-targetability 21 
against NSCLC cells and therapeutic effect. Optimal lipid to drug ratio was selected to 22 
prepare AFT-loaded PSL and CL with desirable physiochemical properties based on 23 
particle size, drug encapsulation efficiency (EE%), stability and release profiles. Moreover, 24 
antitumor activity was performed in vitro on human lung cancer cells (H-1975)  using a 25 
WST-1 assay and Annexin-V apoptosis assay. The mean particle size of the liposomes was 26 
less than 100 nm, and EE% was more than 50% with lipid to drug ratio of 1:0.5. Stability 27 
data showed that PSL and CL were physically stable for 1 months at 4 and 25 oC. In vitro 28 
drug release study demonstrated the sustained release of AFT at pH 7.5; while PSL 29 
exhibited fast drug release in pH 5.5. This effect revealed that PSL showed pH-sensitive 30 
release behaviors. In addition, the in vitro cytotoxicity study was employed for AFT-loaded 31 
PSL due to optimal characterizations. Thus, in vitro anticancer activity revealed that AFT 32 
loaded-PSL triggered apoptosis in H-1975 cells. In addition, the inhibitory effect towards 33 
H-1975 and HCC-827 was observed, indicating, which indicated high antitumor activity 34 
of AFT-loaded PSL. Then, PSL might potentially create practical clinical strategies for 35 
better targetability and delivery of AFT for treatment of lung cancer. 36 
 37 
Key words: Afatinib, pH-sensitive liposomes, In vitro release, Anticancer activity, Lung 38 
cancers 39 
 40 
1. Introduction  41 
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Cancer is a foremost problem of disease worldwide to human health in recent years. 42 
Moreover, lung cancer becomes a serious danger to human health, it is about 1.38 million 43 
cancer-associated mortality in males and females in recent decades [1-2]. The incidence of 44 
lung cancer has increased significantly in recent years in Kingdom of Saudi Arabia and 45 
United Kingdom due to the increased prevalence of cigarette smoking [3-4]. 46 
Approximately 85% of lung cancer diagnoses are classified as non-small cell lung cancer 47 
(NSCLC) and the remaining 15% small cell lung cancer (SCLC) [6]. The unsatisfactory 48 
effects after treatment of lung cancer patients using conventional approaches such as 49 
surgical resection, radiation, and chemotherapy were perceived [6]. The majority of 50 
chemotherapy administration is intravenous, causing pronounced side effects due to their 51 
systemic drug distribution. Moreover, the bioavailability of orally administrated anticancer 52 
agents is usually compromised by the first-pass metabolism [7]. The cytotoxic effects of 53 
chemotherapeutic agents against normal cells, according to dose-response effects, have 54 
been recorded, leading to the patient's frail and death [8]. Therefore, the targeted delivery 55 
of anticancer drugs has become a focus of scientific research. NSCLC treatment can be 56 
improved by targeted delivery of chemotherapeutic agent (s) to suppress the major 57 
signaling pathways involved in lung cancer. Then the targeted delivery of anticancer drugs 58 
directly into the lungs can increase their accumulation in tumor cells and reduce adverse 59 
side effects [9]. To date, numerous epidermal growth factor (EGFR) targeting agents have 60 
been approved, including gefitinib, erlotinib, and lapatinib; however, both primary and 61 
acquired resistance are significant clinical problems [10]. Afatinib (AFT) is a novel, potent, 62 
small-molecule tyrosine kinase inhibitor (TKI), which is now marketed (2013), as a film-63 
coated oral tablet as a dimaleate salt. AFT is an especially effective treatment for nonsmall 64 
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cell lung cancer (NSCLC) [11]. AFT has ability to bind covalently and irreversibly to the 65 
intracellular TK domain, preventing intracellular signaling [12]. By targeting ErbB family 66 
receptors, AFT blocks a wide spectrum of cancer-associated ErbB-driven pathways, and 67 
thus has broader antitumor activity against receptors with acquired mutations that are 68 
resistant to the first generation of TKIs [13]. AFT exposed at low concentration in the 69 
tumor cells, which reduced their clinical uses [14]. Therefore, the targeted delivery of AFT 70 
has become a focus of scientific research. Nanomedicine is extensively used due to their 71 
intrinsic properties such as improved cancer therapy with reduced toxicity. The 72 
nanoparticles may be considered as a promising antitumor delivery system for AFT, which 73 
may trigger its delivery to the cancer tissues [15]. The liposomes were the interest type of 74 
nanomedicine for clinical application in the field of cancer therapy [16]. In addition, they 75 
have ability to target tumor tissues via an enhanced permeation and retention (EPR) effect 76 
[15]. Liposomes are suitable carriers for pulmonary drug delivery owing to their capacity 77 
for targeting to specific cells/tissues [17]. Although drug-loaded liposomes can extend in 78 
vivo circulation and increase chemotherapeutic activity, they may also be limited targeting 79 
and fast cleared [18]. It has been reported that pH-sensitive liposomes have received great 80 
attention due to their efficient accumulation in the tumor cells [19]. It has been described 81 
that tumor tissues exhibited an acidic condition (pH 5.0-6.5) than normal tissues (pH 7.4-82 
7.5) [20]. Therefore, pH-sensitive liposomes were able to deliver the drugs into the tumor 83 
cells when the pH value is lower than the normal tissue. Therefore, it may be expected that 84 
pH-sensitive liposomes are more efficient for the delivery of AFT than conventional 85 
liposomes due to their fusogenic character [21]. pH-sensitive liposomes could increase the 86 
intracellular delivery of their content in cancer cells [20-21]. To the best of our knowledge, 87 
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only one study investigated AFT nanoparticles in term of polymeric micelles as a 88 
pulmonary delivery system that improved the therapeutic efficacy in HER2-overexpressed 89 
HCT-15-induced tumors [22].  90 
In this study, we have prepared three types of liposomes, pH-sensitive liposomes 91 
compared with conventional and cationic liposomes containing AFT to study their cancer 92 
targeting. An HPLC method was developed and validated for AFT for in vitro analysis.  93 
The liposomes were characterized in term of particle size distribution, zeta potential and 94 
encapsulation efficiency. The surface morphology of the desired liposome was observed 95 
by TEM. Moreover, the drug release of AFT was investigated for pH sensitivity (pH 5.5) 96 
and prolonged circulation (pH 7.4). The stability studies of these liposomes were 97 
performed at a different temperature. Afterward, the NSCLC cells (H-1975 cells) were 98 
selected for the assessment of antitumor activity of the optimum liposomes using a 99 
colorimetric WST-1 assay and flow cytometry. Moreover, the apoptosis in different cells 100 
like H-1975, HCC-827 and H-1650 was established after incubation with liposomes. 101 
2. Materials and methods 102 
2.1. Materials 103 
AFT (99.8% purity) was purchased from Green Stone Swiss Co., Limited. 1,2-104 
distearoyl-sn-glycero-3-phosphocholine [18:0] (DSPC), 1,2-dioleoyl-sn-glycero-3-105 
phosphoethanolamine [18:1] (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine [18:1] 106 
(DOPC), and 1,2-dioleoy-3-trimethylammonium-propane Chloride salt (DOTAP) were 107 
kindly gifted by Avanti Polar Lipid. Cholesteryl hemisuccinate (CHEMS) was purchased 108 
from Avanti Polar Lipid. H1975, H-1650, and HCC827 cells were obtained from the 109 
American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained 110 
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at 37°C and 5% CO2 in RPMI 1640 medium (GIBCO®, SIGMA-ALDRICH, Saint Louis, 111 
USA) containing 10% fetal bovine serum (FBS) and1% antibiotic/antimycotic which were 112 
purchased from (GIBCO®, InvitrogenTM, Carlsbad, USA). All other reagents and 113 
chemicals were of analytical grade. 114 
2.2. HPLC assay of AFT  115 
2.2.1. HPLC instrumentation  116 
A Water Breeze2TM HPLC system (Waters Corporation, Milford, U.S.A) was used 117 
for method development. The HPLC system equipped with an automated sampling system 118 
(WatersTM 2695 Plus Autosampler, USA) at 4°C and a photodiode array detector 119 
(WatersTM 2998, USA). The HPLC system was examined by “Breeze2 (WaterTM)” 120 
software. AFT was analyzed using mobile phase that consisted of A: 0.1% triethanolamine 121 
and 1% acetonitrile in HPLC water (pH= 6), and B: acetonitrile and 10% methanol at a 122 
flow rate of 1 mL/min. The mobile phase flowed over a reversed-phase C18 column 123 
(WaterTM, 3 x 150 mm, 3.5 µm particle size) coupled with a C18 guard cartridge (4×2.0 124 
mm) and maintained at 50 oC. The injection volume of each AFT sample was 10 μl and 125 
detected by the UV detector at 253 nm. All the operations were carried out at room 126 
temperature. 127 
2.2.2. HPLC assay 128 
A stock solution of AFT was prepared in methanol at a concentration of 1 mg/ml 129 
and stored in 4.0 ml amber glass vials at -20°C. Serial dilutions in mobile phase were 130 
performed in the range of 0.01 to 25 µg/ml to produce a standard calibration curve and 131 
stored at -20°C. A daily standard calibration curve (n=3) ranging from 0.01 to 25 µg/ml 132 
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was prepared to determine the unknown AFT concentrations for entrapment efficiency and 133 
drug release.   134 
2.2.3. Method validation 135 
The validation of HPLC method was conducted according to the International 136 
Conference on Harmonization (ICH) guidelines. The following items were considered for 137 
validation: linearity, accuracy, precision, specificity, limit of detection (LOD), limit of 138 
quantification (LOQ) and robustness. Three standard calibration lines were prepared at 139 
different times (3 months) to evaluate the linearity, precision, accuracy, and stability of the 140 
method.  141 
Linearity was assessed by calculating a regression line by plotting the peak area of 142 
AFT vs. the AFT concentration ranging from 0.01 to 25 µg/ml.  143 
The accuracy was determined via the analysis of multiple replicates (n = 6) of AFT 144 
concentration. The accuracy of the method was expressed in term of bias. 145 
The precision of a quantitative method was determined by repeatability as intra-day 146 
precision by an analysis of three replicates of AFT concentrations over the same day. Inter-147 
day precision was determined by the analysis of three replicates of various AFT 148 
concentrations over three different days. The results were expressed as the relative standard 149 
deviation (RSD%).  150 
Low, medium, and high concentration quality control (QC) samples at 151 
concentrations of (100, 1,000 and 10,000 ng/ml AFT, respectively) were analyzed, on three 152 
distinct occasions within at least 3 months, as before described.  153 
The LOD and LOQ were determined from the calibration curve obtained using six 154 
replicates that were closest to the LOQ. The following equations were used: 155 
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LOD = 3.3 σ/S       Eq. 1 156 
LOQ = 10  σ/S      Eq. 2 157 
LOD and LOQ were determined based upon the slope (S) of the calibration curve 158 
and least standard deviation obtained from the response (σ). It has a low limit of 159 
quantitation (5 ng/ml) with satisfactory specificity, no matrix interference was observed.  160 
These findings demonstrated that the assay has good selectivity.   161 
2.3. Preparation of liposomes 162 
Different types of AFT-loaded liposomes were fabricated by thin-film hydration 163 
method followed by extrusion as described previously [23]. Non-targeting liposomes (NL) 164 
were prepared using DSPC, DOPC, and DOPE at molar ratios of 3: 3: 10. Moreover, three 165 
parts of the 10 parts of DOPC of the total liposomal contents were replaced by DOTAP or 166 
CHEMS to form cationic and pH-sensitive liposomes, respectively. The AFT was added 167 
to the lipids at ratios of 0.25:1, 0.5:1, 0.75:1, 1:1, 1.25:1 and 1.5:1 (w:w), respectively. The 168 
composition of the liposomes was presented in Table 1. Briefly, AFT and lipids were 169 
dissolved in chloroform, in a round bottom flask following by evaporation to obtain dried 170 
thin film at 55 oC using a rotary evaporator (Buchi Rotavapor R-200, Switzerland). The 171 
resulting lipid film was hydrated with the proper volume of phosphate buffer saline (PBS; 172 
pH 7.4) by gently mixing for 30 min at 55 oC to produce multilamellar vesicles (MLVs). 173 
The liposomes were subjected to extrusion through polycarbonate membranes with two 174 
pore sizes (200 and 100 mm) using a discontinuous extruder (Liposo-Fast™ Avestin Inc., 175 
Ottawa, Canada). The liposomes were extruded 5 times through a polycarbonate membrane 176 
with a pore size of 200 nm following by 21 times through 100 nm at low pressure (200 177 
psi). The three types of plain liposomes were prepared similarly. The final formulations 178 
were stored for overnight at 4°C.  179 
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2.4. Physicochemical characterization of liposomes 180 
2.4.1. Particles size distribution and zeta potential 181 
The mean vesicle sizes, size distribution and the zeta potential (ζ) were 182 
characterized by dynamic light scattering (DLS) at 25 oC with a fixed angle of 137° using 183 
a Zetasizer Nano ZS (Malvern Instruments Ltd., UK). The liposomes were appropriately 184 
diluted with purified and filtered water (0.2 m pore size) prior to the measurements. The 185 
mean vesicle diameters were the averages of five measurements. All measurements were 186 
done in triplicate. 187 
 188 
2.4.2. Encapsulation efficiency  189 
Due to the poor solubility of AFT, the free AFT occurred in two forms in the 190 
external phase of the liposomal dispersion like free undissolved and free dissolved AFT. 191 
The free undissolved AFT was separated from the liposomes using light centrifugation. 192 
Meanwhile, the supernatant (encapsulated and free dissolved AFT) were filled into 193 
centrifuge tubes and ultra-centrifuged at 40000 rpm at 4 ◦C. The clear supernatant which 194 
contained the free dissolved AFT was collected. The total AFT regard to the sum of both 195 
encapsulated and free AFT that is existed in the liposomal preparation. The concentration 196 
of total AFT was determined after dissolving and disrupting of the liposomal dispersion in 197 
methanol and triton x-100 using a vortex mixer, followed by centrifugation for 15 min. The 198 
clear supernatant which contained the total AFT was then transferred to a new tube and 199 
kept at 4 ◦C until analysis.  200 
 The drug encapsulation efficiency (EE%) was calculated using the total drug 201 
content of liposomal (AFTtotal) dispersion and un-entrapped drug content of the dispersion 202 
(AFTfree). The EE% of all the formulation was calculated by using the following formula:  203 
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 x100
AFT
AFT -AFT
  EE%
 toal
free total       Eq. 3 204 
2.4.3. Morphology of liposomes 205 
The morphology of selected liposomes was visualized by transmission electron 206 
microscope (TEM) using a JEM-2100 electron microscope (Jeol, Tokyo, Japan). Briefly, a 207 
drop of diluted liposomes was applied to a copper grid and the excess liquid was removed 208 
using filter paper. The samples were air-dried for 15 min and observed by TEM. 209 
2.4.4. Stability study 210 
The physical stability of the selected liposomes was conducted to monitor the 211 
physical stability of AFT loaded liposome formulations (Table 2). All liposomal 212 
formulations were stored in glass vials at 4±1 °C and 25°C ± 2°C for a period of one month. 213 
The stability was evaluated by measuring the average particle size, ζ and PDI during the 214 
storage. The AFT content was evaluated by HPLC. The physicochemical stability of the 215 
freshly prepared formulation (at day1) was used as the control and the AFT content on day 216 
1 was normalized to 100%. 217 
2.4.5. In vitro drug release 218 
In vitro release profile of AFT from of NL, CL, and PSL (selected liposomes) were 219 
evaluated using the Franz diffusion cell system (FDC-6, LOGAN, Instruments 220 
Corporation, USA). The experiments were conducted in 7 ml of PBS buffer (pH 7.4 and 221 
5.5) with 0.2% Tween 80 to maintain sink condition. The cellophane dialysis membranes 222 
(molecular weight cut off: 12-14 KDa) were soaked before use in distilled water at room 223 
temperature for 12 h prior to use to ensure its wetting. An aliquot of 100 μL liposomes was 224 
added into donor chambers, ensuring there were no air bubbles under the membrane. The 225 
receptor compartment consisted of PBS at pH 7.4 for all liposomes  and pH 5.5 for PSL at 226 
11 
 
37 °C, and stirring at 150 rpm. Samples of 500 μL were withdrawn at various time intervals 227 
up to 24 h, and replaced immediately with the equal volume of fresh re-heated PBS. The 228 
amount of AFT in each sample was analyzed by HPLC. The experiments were performed 229 
in triplicate. The data of in vitro AFT release were fitted to various kinetic equations, 230 
including zero order, first order, Higuchi’s model and Korsmeyer Peppas plot and R2.  231 
Then, n values (diffusion exponent) were calculated for each linear curve obtained by the 232 
regression analysis of each kinetic equation [24]. 233 
2.5. Antitumor activity studies 234 
2.5.1. Cell proliferation assay, WST-1 235 
The in vitro cytotoxicity of AFT compared to different chemotherapeutic agents 236 
(carboplatin, gemacitabine and paclitaxel) was determined using WST-1 using NSCLC 237 
cells (H-1975 cells). In brief, the cells were seeded into 96-well plates at a density of 104 238 
cells/well and incubated overnight in culture medium. Afterward, different concentrations 239 
of 1, 5, 10, 20, 40 and 80 M were added to each well and incubated for additional 24 h. 240 
At the end of the treatment, a 10 µl of cell proliferation reagent WST-1 kit was added and 241 
incubated for 4 h at 37 oC. The intensities of photometric metabolite (formazan) were 242 
measured at 450 nm using an xMark™ Microplate Absorbance Spectrophotometer (Bio-243 
Rad Laboratories, Inc., Hercules, CA, USA). The results are expressed as the IC50, which 244 
was obtained graphically using SigmaPlot 10 (SYSTAT Software, Inc., San Diego CA, 245 
USA). 246 
2.5.2. Annexin-V apoptosis assay 247 
Cell death was assessed using the Vybrant® Apoptosis Assay kit and flow 248 
cytometry. The H-1975 cells were seeded in six-well plates at 7 x 104 per well and 249 
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incubated overnight. Then, the cells were treated with pure AFT (control) and AFT loaded 250 
PSL at concentrations of 0.5, 1, 3, 5 and 8 m for 24 h after dilution with culture medium. 251 
After treatment, the cells were harvested by trypsinization and centrifuged, and re-252 
suspended in PBS. The cells were stained with Alexa Fluor® 488 Annexin V/propidium 253 
iodide (PI) and analyzed using the flow cytometer. The percentage of cell death was 254 
determined using FACS-CaliburTM apparatus and CellQuest Pro software (Becton-255 
Dikinson Biosciences, Franklin Lakes. NJ, USA). Moreover, the apoptosis in different cells 256 
like H-1975, HCC-827 and H-1650 was tested after application of NL, CL and PSL at 0.25, 257 
0.5, 0.75, 1 and 2 µM. Furthermore, the percentage of cell death in  the wells containing 258 
the free drug and PSL following a 48 and 72h incubation period was subsequently 259 
compared with the results of 24 h incubation at 0.25, 0.5, 0.75, 1 and 2 µM.  260 
2.6. Statistical analysis 261 
 Quantitative data were expressed as the mean ± SD of at least three replicates. The 262 
Student’s t-test and one-way analysis of variance (ANOVA) using IBMSPSS Statistics 21 263 
was used to assess multiple comparisons between different methods and times. The level 264 
of confidence was set as 95%.  265 
3. Results  266 
3.1. HPLC assay 267 
Three HPLC methods have been described for AFT quantification in dosage forms 268 
[25]. This method has been reported by Vejendle et al, which demonstrated a lack of 269 
sensitivity with LOD (60 ng/ml) and a longer run time (20 min). Therefore, A new sensitive 270 
HPLC method for AFT analysis was developed in the current study. This method was used 271 
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to quantify the AFT concentration for its in vitro studies. The method was determined to 272 
be specific for AFT in the matrix with no interfering peaks.  273 
 It was identified in our laboratory that the maximum absorbance for AFT is at 206 274 
and 253 nm. While, the HPLC analytical methods reported in the literature detected AFT 275 
at 252, 258 or 268 nm. Therefore, the detection wavelength of 253 nm was used for a better 276 
sense of AFT in the HPLC in this study. As shown in Fig. 1, the average  retention time 277 
was 2.4 min, with no interfering peaks in chromatogram A (the blank) and chromatograms 278 
B, C (AFT). The obtained results indicated the specificity of the HPLC assay method. It 279 
should be mentioned that, during the in vitro studies, there was no interfering peaks from 280 
the NP ingredients co-eluted with the AFT peak, which further confirmed the specificity 281 
of the method.  282 
3.2. Method validation 283 
A calibration curve of the peak area of AFT vs. the various AFT concentrations, in 284 
the range of 0.01 to 25 µg/ml was conducted. The regression equation of the line was 285 
obtained (y = 360232x + 56.95) resulting in the correlation coefficient (R2) of 0.9999. The 286 
results indicated the quality of the curve (data not shown). Therefore, there was a good 287 
linear relationship between the AFT peak area and its tested concentrations. 288 
The analytical method was validated in terms of linearity, precision, and accuracy. 289 
Linearity was assessed using a calibration curve to investigate the ability of this method to 290 
get a proportional response to the different concentrations. Based on the concentrations 291 
used ranged from 10 to 250000 ng/m, in triplicate, the linearity was evaluated and a 292 
calibration curve was constructed.  293 
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The LOD was determined to be 10 ng/ml and the LOQ was 5 ng/ml, with the 294 
corresponding CV values of 1.8 and 0.93 %, respectively (Table 2).  295 
For precision and accuracy of sample analysis, AFT standard solutions of three 296 
replicates were prepared in triplicate, and analyzed on the same day (repeatability) or in 297 
three different days (intermediate precision). Tables 3 showed that the precision did not 298 
exceed the required RSD value with maximum RSD value was < 1.98 %. Analysis of 299 
variance of the data indicated no significant difference (p =0.401) in the slopes, intra- and 300 
inter-day of the calibration curves. The results confirmed the reproducibility of the assay. 301 
The accuracy was more than 99.9 %.  302 
The method was found to be robust, since small variations in the method conditions 303 
had a negligible effect on the chromatographic behavior of the AFT. The results indicated 304 
that changing of the HPLC system or the C18 column had no effect on the chromatographic 305 
behavior of AFT. Even a small change in the mobile phase composition did not 306 
significantly change the peak area of the drug used for this method.  307 
3.3. Particle size distribution and zeta potential  308 
This study aims to evaluate the incorporation of AFT to CL and PSL compared to 309 
NL (control liposomes) for the design of an efficient anticancer delivery system. The 310 
obtained liposomes were characterized in terms of the mean particle size, PDI and ζ values 311 
using DLS and electrophoretic light scattering (Data not shown). The particle size of the 312 
liposomes were ranged from 46 to 57 nm and values of PDI were less than 0.2, which 313 
indicate narrower size distribution indicating no aggregation. Regarding ζ, the liposomes 314 
presented high values according to the increasing lipid to the drug ratios, until the ratio was 315 
1:0.5 (Fig. 2). The AFT-containing liposomes exhibited more positive ζ than liposomes 316 
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without AFT, which proposes that the addition of DOTAP increased the amounts of AFT 317 
in the liposomes. In case of NL, the positive ζ was low and after the incorporation of the 318 
drug, ζ increased by approximately two-fold until 1:0.5 of lipid to the drug ratio. CL 319 
possessed great values of positive ζ ranging from 38.9 mV for the blank to 48.4 mV for the 320 
ratio of 1:0.5. However, PSL exhibited negative values of ζ, due to CHEMS and decreased 321 
with the increasing the drug to lipid ratios (Fig. 2).  322 
3.4. Encapsulation efficiency 323 
The effect of the lipid to drug ratio on the encapsulation of AFT is indicated in Fig. 324 
3. As the lipid to AFT ratios increased, the amount of the drug was increased to a certain 325 
extent and then decreased. The highest values of the encapsulated AFT were on lipid to 326 
drug ratio, 1:0.5, the EE values were 43, 50, and 52 % for NL, PSL, and CL respectively. 327 
As expected, the amount of AFT in the liposomes would increase with increasing of drug 328 
concentration. After reaching the maximum capacity of AFT, EE values were decreased 329 
with more AFT. However, the amount of free drug increased (P< 0.05) significantly, 330 
thereby notably decreasing the EE%.   331 
According to the obtained results, a lipid to drug ratio 1:0.5 in all tested liposomes 332 
was selected for further studies due to the high value of EE%. On the contrary,  PSL at a 333 
lipid to drug ratio of 1:1 showed the lowest EE%.   334 
3.5. Morphology of liposomes 335 
TEM images of PSL are presented in Fig 4. The images showed that PSL were a 336 
spherical shape. In addition, the existence of multilamellar structure was well visualized 337 
inside PSL (Fig. 4). It has been reported that the protonated CHEMS showed a lower 338 
hydration ability than CHEMS at neutral pH, while the protonated amino group of 339 
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phosphatidylethanolamine (PE) exhibited greater hydration ability, thus enhancing the 340 
immiscibility between PE and CHEMS and causing formation of a heterogeneous system 341 
[23].  342 
3.6. Stability study 343 
The short-term stability of the selected liposomes of lipid:drug ratio of 1:0.5 was 344 
investigated for up to 30 days at 4 ± 1 oC and 25 ± 2 oC. This ratio was chosen due to the 345 
highest EE% of AFT. There was no significant change in the particle size, PDI, ζ and AFT 346 
EE% of liposomes during the stability study at 4°C compared to the initial preparation (p 347 
> 0.05). However, at 25 oC, the particle size of the liposomes after storage for 30 days as 348 
47.5±2.3 to 75±3.3 nm, 53.8±2.6 to 84±15.9 nm and 55.3±1.2 to 79.5±2.5 for CL, PSL and 349 
NL respectively. However, liposomes were still smaller than 100 nm. There was no 350 
appreciable change in PDI over 30 days. The ζ at 4°C and 25oC for 30 days exhibited 351 
insignificantly different (p =0.141) compared to the initial formulation. The EE% of AFT 352 
after storage at 4°C and 25°C for 30 days was slightly decreased but was still higher than 353 
90% and 80%, respectively, of the initial formulations (Fig.5). 354 
3.7. In vitro release study 355 
To evaluate the in vitro drug release behaviors of AFT from CL and PSL compared 356 
to NL, these nanoliposomes were incubated in pH 7.4 PBS solutions at 37 oC in (Fig. 6). 357 
Moreover, to determine the pH sensitivity of PSL, the drug release behavior under pH 5.5 358 
was also investigated, and pH 5.5 was selected to mimic the tumor pH (Fig. 6). As weakly 359 
acidic environments are presented in the endosomal and lysosomal of tumor cells [26]. 360 
The AFT release rate was relatively slow in neutral pH 7.4, just reaching 63.6%, 361 
28.1% and 35.6 % for CL, NL, and PSL, respectively within 24 h. These data revealed that 362 
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the liposomes exhibited significantly constant release profiles and AFT was successfully 363 
loaded into the liposomes. However, the cumulative release of AFT in PSL at pH 5.5 364 
reached to 101 % in 4 h, presenting a burst release phenomenon. The release profiles of 365 
AFT from different liposomes apparently biphasic release processes, where rapid release 366 
of the surface-adsorbed AFT was observed during the initial phase (first 4 h), followed by 367 
a slow release profile for up to 24 h. The AFT release was increased significantly with the 368 
pH decreased from 7.4 to 5.5 in case of PSL, and showed reasonably good pH-369 
responsiveness. But, in a physiological environment (pH 7.4), the encapsulated AFT was 370 
released at a constant rate. It indicated that the AFT was well protected inside the liposome 371 
bilayers at physiological pH. But in acidic condition (pH 5.5) cancer environment, the AFT 372 
release was hastened.  Therefore, the release of the PSL containing AFT was controlled by 373 
the environmental pH. This phenomenon are consistent with the obtained results of 374 
doxorubicin release at various pH values [27]. The constant release rate of AFT may 375 
conserve a constant contact of the drug to the cancer cell resulted in improved antitumor 376 
activity and helpful for drug delivery applications. The PSL system has the greatest 377 
potential to improve cancer therapy efficacy. To fit the release kinetics of AFT from 378 
liposomes at pH 5.5 and 7.4, different kinetic models viz. Peppas, Higuchi, zero order and 379 
first order were exploited to predict the drug release profile. These models depend on the 380 
diffusion equations, which based on the composition of liposomes and release conditions. 381 
It was reported that the release of the drug from liposomes could be allocated in three 382 
different mechanisms: diffusion, erosion and diffusion-erosion [28].  It was found that the 383 
results were supported by the Korsmeyer-Peppas model at pH 7.4, which it presented the 384 
highest value of R2. Moreover, the values of n are 0.460, 0.681, 0.431 and 0.599 for CL, 385 
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NL, PSL and PSL (pH 5.5), respectively, indicated a non-Fickian diffusion kinetics (0.5 ˂ 386 
n ˂ 1) [28]. PSL (n=0.431) exposed Fickian diffusion due to slow release at neutral 387 
condition [28]. Subsequently, it is concluded that the drug release mechanism was mainly 388 
owing to the combination of diffusion and erosion of the liposomes containing AFT (Table 389 
4).  390 
Moreover, the release profiles of the three AFT-loaded liposomes could be divided 391 
into two phases, the first phase from 1 to 4 h and the second phase from 6 and 24 h. The 392 
fitting parameters derived from korsmeyer-Peppas  were listed in Table 5. n is the release 393 
exponent indicating the drug release mechanism and k reflected the rate constant of the 394 
release. At pH 7.4, n values of liposomes in the first phase were higher than 0.43, indicating 395 
the release behavior of AFT followed a combination of diffusion and erosion control. In 396 
the second stage, n values of liposomes were below 0.43, except NL, representing a 397 
combination of diffusion and erosion mechanism. The k values for PSL at pH5.5 were 398 
much higher than those of pH 7.4, demonstrating the highest release rate in an acidic 399 
environment. The difference between k values of the first and second stage were nearly the 400 
same, which indicated that the AFT release rate was comparatively slow in a neutral 401 
environment.  402 
 403 
3.8. Cell proliferation assay, WST-1  404 
In general, it is essential to screen and confirm that the antitumor drugs are potent 405 
and efficient for cancer therapy. Therefore, the potency of AFT was evaluated in 406 
comparison with selected drugs depending on their activities against lung cancer in an in 407 
vitro cell-based assay. Half-maximal inhibitory concentration (IC50) of these drugs was 408 
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attained from an experimentally derived dose-response curve. In this study the cytotoxicity 409 
was evaluated with a WST-1 assay in H-1975 cells. The cells were incubated with AFT, 410 
paclitaxel, carboplatin and gemcitabine for 24 h. As shown in Fig. 7, the results detected 411 
that effect of AFT and paclitaxel on H-1975 cells had dose-dependent manner. On the 412 
contrary, the data displayed minor cytotoxicity against H-1975 cells, even up to the highest 413 
doses of carboplatin and gemcitabine. The IC50 values for AFT and paclitaxel were 20 and 414 
25 µM, respectively. Particularly, by increasing the concentrations of AFT to 40 µM, H-415 
1975 cells exhibited higher sensitivity than paclitaxel. The cell viability dropped to 2% 416 
with 40 µM of AFT and 50% with paclitaxel. Further increasing the concentration of AFT 417 
up to 80 µM, the insignificant reduction in the cell viability was observed (Fig. 7). Thus,  418 
in vitro anticancer activity revealed that AFT had potent cytotoxic (IC50 value; 20 µM) as 419 
compared to other drugs. 420 
The cell toxicity of the best liposomes PSL, NL, and CL was also measured by a 421 
WST-1 assay on H-1975 cells (data not shown). Unfortunately, the reduction of cell 422 
viability (H-1975 cells) at any AFT concentrations did not recorded. This behavior 423 
confirmed that the WST-1 assay failed to detect any reduction in viable cell numbers. In 424 
contrast, the cytotoxicity (dose-dependent) was detected by microscopic examination using 425 
1-80 µM of PSL, NL, and CL. Accordingly, the intracellular vacuoles and cell aggregates 426 
at concentrations from 1 to 5 µM was appeared. Further increasing the concentrations from 427 
10 to 80 µM, indefinite aggregates of damaged and dying cells were perceived. The order 428 
of liposomes to kill H-1975 cell was followed as PSL > NL > CL. Therefore, AFT-loaded 429 
PSL at concentrations less than 10 µM were performed in the next study. 430 
3.9. Annexin-V apoptosis assay 431 
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Apoptosis-inducing influence of AFT loaded-PSL formulation was evidenced by 432 
Annexin V/PI protocol. The extent and the nature of the induced cell death were analyzed 433 
by flow cytometry. H-1975 cells were incubated with various concentrations of AFT 434 
loaded-PSL (0.5 - 8 µM) for 24 h, which were selected based on WST-1 assay results. The 435 
amounts of the early apoptotic and the late apoptotic cells, with necrotic cells were 436 
determined after deduction of the proportion of spontaneous apoptosis. The results clearly 437 
revealed that the AFT loaded-PSL triggered both apoptosis in H-1975 cells (Fig. 8A).  438 
The quantities of apoptotic cells increased from 55 to 58.9 % after exposure to 0.5 439 
to 1 µM of AFT loaded PSL. However, increasing the concentration to 8 µM resulted in a 440 
reduction of the quantities of apoptotic cells from 30% at 3 µM to 9 % at 8 µM. 441 
Furthermore, high cell viability of 87.5 % of free liposomes was observed. Concerning the 442 
concentrations of AFT loaded-PSL at 3 to 8 µM, the proportions of necrotic cells increased 443 
as the number of apoptotic cells decreased. The proportions of necrotic cells increased from 444 
3 to 90%,  depending on the concentrations of AFT loaded-PSL at 0.5 and 8 µM (a dose-445 
dependent manner) (Fig. 8B). Consequently, AFT at a concentration of 2.0 μM was 446 
selected due to high apoptotic activity for further cytotoxicity studies using different lung 447 
cancer cell lines.  448 
Moreover, the cell viability of AFT loaded-PSL after H-1975 cells were incubated 449 
for 48 and 72 h in addition to 24 h also was investigated (Fig. 9). The significant cytotoxic 450 
effect in H-1975 cell at a concentration of 2 μM of AFT loaded-PSL, with the total cell 451 
death proportion exceeding 78, 80 and 84 % after 24, 48 and 72 h, respectively. The 452 
cytotoxic effect of the AFT-PSL formulation at a concentration of 2 μM was mainly due 453 
to induced apoptosis, with slight necrosis. For comparison, the cell viability of free 454 
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liposomes at 72 h was 90 %. These results revealed that no significant difference in the cell 455 
death after 24 and 48 h of exposure with H-1975 cells (p > 0.05). Therefore, 24 h of 456 
exposure was selected for further study.  Free liposomes showed insignificance cytotoxic 457 
(apoptosis) after 24 and 48 h of exposure with considerable toxicity (necrosis) after 72 h 458 
of exposure. 459 
Overall, the obtained results clearly revealed the greater anticancer activity of PSL 460 
as shown by a WST-1 assay and apoptosis assay. Therefore, 24 h of exposure was selected 461 
for further cytotoxicity study of AFT-loaded PSL, CL and NL by using different lung 462 
cancer cell lines. Hence, the anticancer activity of these liposomes was performed using 463 
Flow cytometric analysis in the three cell lines as H-1975, H-1650, and HCC-827 (Fig.10 464 
A, B & C). This study was conducted to detect the level of apoptosis induced after 465 
incubation with various concentrations of 0.25, 0.5, 0.75, 1, and 2 µM of each liposomes 466 
for 24 h. While, dimethyl sulfoxide and free liposomes were used as the controls. The 467 
incubation of the cells with free liposomes did not induce notable cytotoxicity (data not 468 
shown). The viability of H-1975 cells decreased more significantly compared to H-1650 469 
and HCC-827 cells (p<0.05). PSL produced highest cytotoxic effect in the different lung 470 
cancer cell lines (H-1975 cells and HCC-827) compared to NL and CL, when using 471 
concentrations 2 µM AFT (Fig. 10). Overall, the results clearly revealed the superior 472 
anticancer activity of PSL as shown by MTT assay and apoptosis assay. 473 
Discussion 474 
It has been reported that the cancer cells exhibited leaky vasculature with gap of 475 
~100 nm, this allows the drug to leak out of the blood vessels and into the cancer cells [29]. 476 
Additionally, cancer cells have an impaired lymphatic system; therefore, substances such 477 
22 
 
as drugs loaded-liposome can be retained for a relatively longer time [30]. This behavior 478 
is commonly referred to EPR effect, which increases the exposure of tumor cells to drug 479 
action. The liposomes have been reported as a potential carrier to target cancer cells. The 480 
liposomes less 100 nm are able to escape the tumor vasculature and accumulate in the cells 481 
by passive targeting [31]. Moreover, the targeted liposomes were designed depending on 482 
the type of phospholipids used. In this study, it has been illustrated that modified liposomes 483 
as PSL can work as an effective carrier for delivery of AFT in vitro. Moreover, this carrier 484 
system presented significant antitumor activity. The desired liposomes can obtained by 485 
investigating different quantities of the drug to lipid  ratios to detect the greatest 486 
encapsulated liposomes. Furthermore, the best liposomes in terms of vesicle size, PDI, ζ 487 
and EE were selected. The in vitro release study and cytotoxicity of the selected liposomes 488 
loaded AFT were examined. In addition, AFT is a potent antitumor drug used in clinical 489 
oncology against a lung tumor. However, AFT had low specificity, systemic toxicity and 490 
indiscriminating of the tumor and healthy tissues [14]. So AFT loaded-lipoosmes were 491 
developed for successful cancer therapy that decreases dose-limiting toxicity. In this study, 492 
a novel pH-sensitive liposomes-based AFT as targeted delivery (PSL) were used to target 493 
tumor cells. It has been observed that PSL has intensely improved the cytotoxicity in 494 
comparison to conventional liposomes (NL) or cationic liposomes (CL). Kraft et al 495 
observed that CL or PSL could accumulate in the lung cells more, compared with NL [32]. 496 
PSL exposed to the destabilization behavior under acidic condition, which lead to rapid 497 
release of its content. It is interesting that the tumor tissues are relatively acidic compared 498 
to the normal tissue site [19-21]. The main difference between these two liposomes is the 499 
composition of phospholipid used. In general, three lipid components: DSPC, DOPC, and 500 
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DOPE. DSPC were used. The rationale for the selection of DSPC was its stability against 501 
chemical degradation due to saturated lipid, which reduces the drug leakage from 502 
liposomes on storage and in vivo transit. To increase the fluidity of liposomal membrane, 503 
DOPC was selected due to its high fluidity at room temperature (transition temperature 504 
(Tm)= −20°C). While, Tm of DSPC is +55 °C, which remains in the gel phase [33]. 505 
Moreover, DOPE was combined to provide fusogenic characters to the liposomes, due to 506 
the formation of an inverted hexagonal phase upon destabilization of membranes at a 507 
mildly acidic pH [34]. Theses lipids possess various chain lengths and degrees of 508 
saturation, which can produce fine-tune the membrane dynamics and phase properties [35]. 509 
The main composition of CL is DOTAP, which is considered as a cationic phospholipid. 510 
While PSL composed from pH-sensitive phosphlipid (CHEMS). The film hydration 511 
method has been used to actively entrap AFT into liposomes with relatively high 512 
efficiencies and small vesicle size (<100 nm) [36]. The PDI values of the obtained 513 
liposomes are less than 0.3 indicating narrow size distribution. The higher ζ, of the obtained 514 
liposomes provoked the potential stability of a liposome. Patil et al investigated the 515 
influence of ζ on the cellular uptake of cerium oxide nanoparticles in A549 lung 516 
adenocarcinoma [37]. Thus, the charged surface of liposomes has ability to attach the cell 517 
membrane. Furthermore, to obtain the liposomes with the highest EE%, the best ratio of 518 
drug to phospholipid was selected for further studies. Accordingly, the highest EE% of 519 
AFT reached to 43.20%, 50.20%, and 52.01% for NL, PSL, CL, respectively at the 1:0.5 520 
ratio of lipid to the drug. Nallamothu et al 2006 indicated that the high EE% of 521 
combretastatin A4 was obtained by increasing the drug to lipid ratios. By using 1:10 to 522 
2:10 of combretastatin A4 to lipid ratios, the amount of the drug increased from 1.05 mg/ml 523 
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to 1.55 mg/ml, respectively. When the drug to lipid ratios was further increased to 4:10, 524 
the EE% of the drug did not increase [38]. Thus, the best liposomes were subjected to 525 
stability study, they exhibited better stability at 4°C or at 25°C after storage for 1 month. 526 
CL showed the highest stability in term of  EE%, particle size and zeta potential. This effect 527 
is due to the inclusion of DOTAP in the liposomes, which decreases the rigidity of the 528 
liposomes with good loading capacity. In vitro drug release data revealed that PSL and NL 529 
exposed sustained release profiles due to the presence of DSPC (Tm), which lead to a 530 
decrease in leakage of AFT in the circulation or extracellular environment. But in case of 531 
CL, AFT exhibited high release rate compared with the other liposomes, at pH 7.4. This is 532 
due to the complete protontion of DOTAP at pH 7.4 [39]. By contrast, the fast drug release 533 
profile of AFT was found after addition PSL in acidic media, which reached to 100% after 534 
4 h. The PSL undergoes destabilization at pH 5.5 and acquire fusogenic properties, thus 535 
tended to rupture and quickly release of AFT. The fusogenic performance of PSL is due to 536 
the presence of DOPE in the lipid layer, which forms a hexagonal structure instead of a 537 
bilayer structure after dispersion in aqueous media. Düzgünes et al showed that liposomes 538 
composed of CHEMS had high stabilize of EE calcein at pH 7.4 and undergo 539 
destabilization and irreversible aggregation under acidic pH [40]. According to the kinetic 540 
models, the release of AFT at pH 7.4 displayed release with Korsmeyer-Peppas model. 541 
This effect is due to early rapid release followed by slow release of the liposomes [41]. In 542 
case of the release pattern of PSL at pH 5.5, AFT release was quite faster with Korsmeyer-543 
Peppas model. This behaviour because AFT exists liposomal membrane, which leaks out 544 
at a faster rate in acidic condition [42]. 545 
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 Therefore, it was confirmed that the pH-sensitive point in the liposome is close to 546 
5 (the tumor microenvironment). PSL might release their content in the acidic environment 547 
of the tumor tissues quickly. Therefore, the PSL were fabricated in the current study to 548 
achieve a certain active targeting toward the tumor. The TEM of PSL revealed uniform, 549 
homogenous and spherical-shaped liposomes with a smooth surface.  550 
The potency of free AFT was compared with selected drugs depending on their 551 
activity against lung cancer. The cell toxicity was evaluated by WST-1 using H-1975 cells. 552 
The WST-1 assay showed that AFT is more effective as a cytotoxic agent compared to 553 
other compounds used in lung cancer treatments (H-1975 cells). Furthermore, the anti-554 
proliferative effect of AFT on H-1975 cells was investigated at various concentrations for 555 
24 h. The results indicated that the inhibition of cell viability AFT had concentration-556 
dependent manners. Moreover, anticancer activity of the obtained liposomes was also 557 
investigated using and H-1975 cells. Unfortunately, WSR-1 assay failed to detect the 558 
anticancer activity of the obtained liposomes due level of interference. However, a detailed 559 
characterization of this interference was not undertaken here. Therefore, the levels of cell 560 
viability between each liposomes were measured by using flow cytometry analysis after 561 
Annexin V/PI staining.  The results of flow cytometry after the treatment of cells with the 562 
AFT loaded-PSL using different concentrations exhibited a comparable level of cell 563 
intensity. It was clearly indicated that the uptake of AFT loaded-PSL by H-1975 cells was 564 
higher than free AFT. The results revealed a marked decline in cell viability with AFT 565 
loaded-PSL up to 60.4% of cell apoptosis at 1 µM after 24 h. The free AFT resulted in 566 
apoptosis in 11.88% of the cells after 24 h. The low cytotoxic effect of free AFT could be 567 
attributed to the low cellular uptake and poor trans-membrane permeability. Of the three 568 
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cancer cell lines tested, H-1975 cells appeared more sensitive to the liposomes. 569 
Particularly, the cytotoxicity of PSL is high compared with that of CL and NL. It is possible 570 
that PSL released AFT in response to the lowered pH in the endosome, and thus facilitated 571 
diffusion of the released AFT from the endosome to the cytosol. It has been suggested that 572 
pH-sensitive liposomes are internalized more efficiently than non-pH-sensitive 573 
formulations [43]. It is notable that the destabilization of PSL at the endosomal 574 
demonstrated that the efficacy of PSL depends on the pH of the tumor tissues [34]. 575 
Additionally, the liposomes containing CHEMS  release their contents into the cytoplasm 576 
from 5 to 15 min upon their incubation with the cells [44]. The destabilization of PSL 577 
induced by acidification of the endosomal lumen represents the most important stage in the 578 
process of intracellular delivery. Carvalho et al developed cisplatin loaded-PSL to treat the 579 
SCLC. Compared with free cisplatin, the cytotoxicity of this PSL was significantly 580 
enhanced [7]. Kim et al developed a PSL with an efficient and targeted delivery system for 581 
gemcitabine, and represent a useful, novel treatment approach for tumors that overexpress 582 
EGFR [45]. More, the cationic liposomes containing paclitaxel composed of DOTAP were 583 
able to significantly decrease tumor perfusion and vascular diameter and the progress of A-Mel-584 
3 melanoma in mouse models [46]. The association of cationic liposomes with surface 585 
membrane is due to the presence of anionic glycoproteins, such as sialic acid rich 586 
glycoproteins [47]. Furthermore, pH-sensitive liposomes containing cytarabine have been 587 
shown greatly antitumor effectiveness in both human HepG2 hepatoma cells and normal 588 
human liver L02 cells compared to non-pH-sensitive liposomes [48]. These promising 589 
results are required further in vivo analysis to understand the biodistribution profile of AFT 590 
loaded PSL to achieve new targeted-formulation for the tumor therapy. 591 
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4. Conclusion 592 
In this work, a novel AFT-loaded PSL for targeted therapy of lung cancer (NSCLC) 593 
were developed. For comparison purpose, AFT-loaded NL, CL and PSL were successfully 594 
designed. The obtained liposomes showed small particle less than 100 nm with a low PDI 595 
(<0.27) and acceptable zeta potential with a spherical shape. The highest EE% values of 596 
the liposomes were achieved according the following order: CL>PSL>NL. The selected 597 
liposomes were stable at 4 and 25°C for 1 month. The PSL, CL and NL showed slow 598 
release profiles in pH 7.4. However, in acidic pH values, PSL exhibited fast release, which 599 
improved its tumor targetability. The selected liposomes revealed efficiency on cancer cells 600 
(NSCLC). Moreover, AFT-loaded PSL inhibited the cell growth of lung cancer cells more 601 
efficiently than free AFT, CL and NL based on using Annexin V assay. The obtained data 602 
indicate that AFT-loaded PSL is a promising a targeted drug delivery for cancer therapy.  603 
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Table 1 738 
Compositions of different types of liposomes. 739 
 Amount required (µmol/mL) 
Phospholipids* NL PSL CL 
DSPC 3 3 3 
DOPC 10 7 7 
DOPE 3 3 3 
CHEMS - 3 - 
DOTAP - - 3 
 740 
*NL: Non-targetin liposomes; CL: Cationic liposomes; PSL: pH-sensitive liposomes; 741 
DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine[18:0]; DOPC: 1,2-dioleoyl-sn-742 
glycero-3-phosphocholine [18:1]; DOPE:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 743 
[18:1]; CHEMS: Cholesteryl hemisuccinate; DOTAP:1,2-dioleoy-3-trimethylammonium-744 
propane Chloride salt (DOTAP) 745 
  746 
 747 
 748 
 749 
 750 
 751 
 752 
 753 
 754 
 755 
 756 
 757 
 758 
 759 
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 760 
 761 
Table 2 762 
Precision of the developed method for analysis of AFT. 763 
Nominal   
(µg/mL) 
Concentrations 
Mean ± SD 
CV% 
0.01 0.01 ± 6.09 0.9266 
0.05 0.05 ± 6.40 0.8051 
0.1 0.1 ± 5.71 1.7143 
0.25 0.25 ± 1.76 0.7076 
0.5 0.5 ± 5.70 1.1404 
1 1 ± 1.77 0.1763 
2 2 ± 4.03 2.3016 
5 5 ± 5.65 1.0731 
10 10 ± 3.76 1.3577 
20 20 ± 3.83 0.1992 
25 25 ± 2.55 0.1102 
 764 
SD: standard deviation; CV: Coefficient of variation percetage 765 
 766 
 767 
 768 
 769 
 770 
 771 
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Table 3 776 
Repeatability for different levels of AFT (n = 3). 777 
Concentration 
(µg/ml) 
Mean ± SDa Precision 
RSDb (%) 
Accuracy 
 (%) 
Inter day     
0.1 99.98 ± 1.98 1.98 99.9 
1 1000.72 ± 0.49 0.05 102 
10 10000 ± 113.26 1.13 100.1 
Intra-day     
0.1 100 ± 1.06 1.07 99.86 
1 1000 ± 0.29 0.03 100.5 
10 10000 ± 60.08 0.6008 100.2 
a   Standard deviation of the mean 778 
b   Relative standard deviation 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
 788 
 789 
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 791 
 792 
 793 
 794 
 795 
Table 1 796 
Release kinetics of AFT release from different liposomes.  797 
pH 
media 
Codes Zero order First 
order 
Higuchi 
(Diffusion) 
Korsmeyer 
Peppas 
"n" value 
 CL 0.691 0.559 0.871 0.940 0.460 
pH 7.4 NL 0.928 0.731 0.988 0.994 0.681 
 PSL 0.754 0.634 0.912 0.971 0.431 
pH 5.5 PSL 0.647 0.486 0.835 0.889 0.599 
 798 
 799 
 800 
 801 
 802 
 803 
 804 
 805 
 806 
 807 
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 808 
 809 
 810 
 811 
 812 
 813 
Table 5 814 
 Drug release kinetics parameters derived from Korsmeyer Peppas. 815 
pH 
media 
Codes an1 
ak1 
bn2 
bk2 
 CL 0.675 16.987 0.168 37.619 
pH 7.4 NL 0.681 3.606 0.527 5.434 
 PSL 0.483 8.809 0.201 16.381 
pH5.5 PSL 0.941 20.910 0.181 59.671 
 816 
aThe first stage is 0-4 h. bThe second stage is 6-24 h. 817 
 818 
 819 
 820 
 821 
 822 
 823 
 824 
 825 
 826 
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Fig. 1 827 
 828 
 829 
 830 
 831 
 832 
 833 
 834 
 835 
 836 
 837 
 838 
Fig. 2 839 
 840 
A 
B C 
Fig. 1. HPLC chromatograms of the mobile phase (chromatogram A), and HPLC chromatograms 
of the mobile phase containing (B) 10 ng/ml and (C) 50 ng/ml afatinib. 
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Fig. 3 852 
-30
-15
0
15
30
45
60
B
la
n
k
(1
:0
.2
5
)
(1
:0
.5
)
(1
:0
.7
5
)
(1
:1
)
(1
:1
.2
5
)
(1
:1
.5
)
Z
e
ta
 P
o
te
n
ti
a
l 
(m
v
)
Drug: Lipid ratio
NL CL PSL
Fig. 2. Zeta potentials of afatinib-loaded liposomal formulations at different lipid to drug 
ratios. 
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Fig. 3. EE% of afatinib-loaded different liposomal formulations with different lipid to 
drug ratios. 
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Fig. 5 899 
 900 
A C 
B D 
Fig. 4. TEM micrographs of the pH sensitive liposome at a drug to lipid ratio 
of 1:0.5 (PSL), using varied magnification power. 
41 
 
 901 
 902 
 903 
 904 
 905 
 906 
 907 
 908 
 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
 919 
 920 
Fig. 6 921 
 922 
Fig. 5. In vitro  release profiles of the liposomal formulations loaded with afatinib in 
phosphate-buffered saline containing 0.2% Tween 80 at pH 7.4 and pH 5.4. Values are 
presented as the mean ± SD. 
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Fig. 6. EE % of afatinib at the ratio 1:0.5, following storage for one month at 4 and 25°C, of 
NL (nontargeting liposome), PSL (pH sensitive liposome) and CL (cationic liposome), P = 
0.141. 
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Fig. 8 950 
 951 
Fig. 7. Cytotoxicity of afatinib, carboplatin, gemcitabine and paclitaxel on H-1975 cells, as 
determined by a WST-1 assay. Cells were treated with varying concentrations of the drugs for 
24 h. Results are from three independent experiments and are expressed as the mean ± SD. 
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Fig. 8. H-1975 lung cancer cells were either treated with free liposomes, as controls, or challenged 
with Afatinib loaded liposomes (PSL2) for 24 hrs, and then the proportion of apoptosis and necrosis 
was analysed by Annexin V/PI-flowCytometry. four groups of cells, viable cells that excluded both 
Annexin V and PI (Annexin V/PI), bottom left; early apoptotic cells that were only stained with 
Annexin V (Annexin V+/PI), bottom right; late apoptotic cells that were stained with both Annexin 
V and PI (Annexin V+/ P+), top right and necrotic cells that were only stained with PI (Annexin 
V/PI+), top left. (A) Flow charts. (B) Histogram showing the percentage of induced apoptosis in H-
1975cells. 
45 
 
Fig. 9 956 
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 965 
Fig. 10 966 
Fig. 9. H-1975 cells were challenged with pH-sensitive liposomes (PSL) (0.25-2 μM) for 24, 48 or 
72 h, following which apoptosis was analysed with Annexin V/PI-flow cytometry. Each value 
represents the mean ± SD of three independent experiments performed in triplicate. 
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Fig.10. Non-small cell lung cancer cells were either treated with Blank 
Liposomes, as control, or challenged with AFT and AFT-loaded liposomes (PSL, 
NL, CL) for 24 h, following which the proportion of apoptotic cells was analysed 
using Annexin V/PI-flow cytometry. Histogram shows the percentage of induced 
apoptosis in H-1975 cells. Each point represents the mean ± SD of three 
independent experiments performed in duplicate. 
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